Articles

This Stream includes all of our Articles Flipbooks

  • Q&A with Dr. Nathaniel Katz

    Q&A with Dr. Nathaniel Katz

    Dr. Katz, Chief Science Officer and the founder of Analgesic Solutions, shared his insights during a recent conversation with Mark Opler, MD, PhD, Chief Research Officer at WCG’s MedAvante-ProPhase.

    Read Flipbook
  • Optimizing SUSAR distribution in a connected– but unharmonized–world

    Optimizing SUSAR distribution in a connected– but unharmonized–world

    Steven Beales and Joe O’Rourke, vice president, business development talk through some of the difficulties Sponsors face when it comes to safety letter distribution, and how to overcome them.

    Read Flipbook
  • Request a Genetics in Clinical Trials training session

    What You'll Learn
  • Quality First: Using Data to Inform Site Selection in CNS

    Quality First: Using Data to Inform Site Selection in CNS

    WCG MedAvante-ProPhase espouses a rather simple philosophy: minimize variability, generate cleaner data.

    Read Flipbook
  • Don’t Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise

    Don’t Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise

    Due to evolving practices and increased regulatory attention on expert committee operations, sponsors are turning more to independent providers with experience in managing expert committees.

    Read Flipbook
  • Protecting Sponsors Against Bias and Variability

    Protecting Sponsors Against Bias and Variability

    Applied Clinical Trials recently spoke with Mark Opler, PhD, MPH, chief research officer of WCG, MedAvante-ProPhase, to learn why placebo response is the leading cause of failed trials.

    Read Flipbook
  • Social Media Company Matches Sponsors with Patients to Advise on Trial Design Evidence Program

    Social Media Company Matches Sponsors with Patients to Advise on Trial Design Evidence Program

    Read Flipbook
  • Benchmark your study enrollment versus competitors

    Get Benchmark Data
  • Q&A with CNS Expert, Dr. Andrew Cutler

    Q&A with CNS Expert, Dr. Andrew Cutler

    Dr. Cutler, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.

    Read Flipbook
  • ×

    First Name
    Last Name
    Company
    Thank you!
    Error - something went wrong!
  • Q&A with CNS Expert, Dr. Philip Scheltens

    Q&A with CNS Expert, Dr. Philip Scheltens

    Philip Scheltens, MD, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Christopher Randolph, PhD, ABPP-CN, chief scientific officer...

    Read Flipbook
  • SNAPSI: Bridging the Gap Between Research and Clinical Care in Mental Health

    SNAPSI: Bridging the Gap Between Research and Clinical Care in Mental Health

    In the field of mental health, there is a discrepancy between how research is conducted and how care is delivered. MedAvante-ProPhase, a WCG company, is collaborating with leaders in health care to...

    Read Flipbook
  • Q&A with Dr. Sofija Jovic

    Q&A with Dr. Sofija Jovic

    Increasingly, sponsors are turning to experts who have “been there, done that” to help them develop protocols for their CNS trials. In this wide-ranging interview, Sofija Jovic, PhD, MBA, of WCG...

    Read Flipbook
  • Q&A with CNS Expert, Dr. Leo Verhagen Metman

    Q&A with CNS Expert, Dr. Leo Verhagen Metman

    Leo Verhagen Metman, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation...

    Read Flipbook
  • Assessing the Sources of Unreliability in Failed Clinical Trials Using PANSS

    Assessing the Sources of Unreliability in Failed Clinical Trials Using PANSS

    Read Flipbook
  • Effect of parental age on treatment response in adolescents with schizophrenia

    Effect of parental age on treatment response in adolescents with schizophrenia

    Read Flipbook
  • The brief negative symptom scale (BNSS): Sensitivity to treatment effects

    The brief negative symptom scale (BNSS): Sensitivity to treatment effects

    Read Flipbook
  • Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia

    Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia

    The aim of this paper is to discuss how the measurement gap between research and clinical care in schizophrenia can be closed.

    Read Flipbook
  • A Developmental History of the Positive and Negative Syndrome Scale (PANSS)

    A Developmental History of the Positive and Negative Syndrome Scale (PANSS)

    In this review article, the authors explore the history of the most influential schizophrenia research tools that have been created over the past several decades.

    Read Flipbook
  • Q&A with CNS Expert, Dr. Scott J. Hunter

    Q&A with CNS Expert, Dr. Scott J. Hunter

    Scott J. Hunter, PhD, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...

    Read Flipbook
  • Q&A with CNS Expert, Dr. Michael Liebowitz

    Q&A with CNS Expert, Dr. Michael Liebowitz

    Dr. Michael Liebowitz, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with...

    Read Flipbook
  • The Right Way to Use Genetic Information in Clinical Trials

    The Right Way to Use Genetic Information in Clinical Trials

    Read Flipbook
  • Q&A with CNS Expert, Dr. Leslie Citrome

    Q&A with CNS Expert, Dr. Leslie Citrome

    Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.

    Read Flipbook
  • loading
    Loading More...